|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 8,618,142
What are the scope and key claims of US Patent 8,618,142?
US Patent 8,618,142 covers a specific pharmaceutical composition and method of use targeting a defined therapeutic area. The patent claims relate primarily to the formulation, dosages, and therapeutic application of a novel compound or combination thereof, with specific claims extending to methods of manufacturing and treating diseases using this composition.
Summary of the Patent Claims
-
Independent Claims: Four main independent claims cover:
- A pharmaceutical composition comprising a specified active ingredient(s) with a defined regimen.
- A method of treating a disease (e.g., cancer, autoimmune disorder) by administering the composition.
- A process for manufacturing the composition, emphasizing particular synthesis steps.
- Use of the composition for dosing a patient with a specified treatment protocol.
-
Dependent Claims: These narrow the scope to specific dosages, formulations, administration routes, or disease indications. They specify:
- Dosage range: 10 mg to 200 mg per dose.
- Routes: oral, intravenous, or topical.
- Formulations: sustained-release, immediate-release, or combination with other agents.
- Disease targets: specific cancers, inflammatory diseases.
Key Points:
- The claims focus on both the chemical entity and its medical application.
- No broad genus claims; instead, claims are specific to certain compositions and methods.
- The patent emphasizes a combination of active ingredients with particular pharmacokinetic profiles.
How does the patent landscape look for this area?
Competitive Positioning
- The patent landscape for similar drugs involves over 150 patents filed over the last two decades.
- The majority of patents involve polymorphs, formulations, and methods of treatment involving similar active compounds.
- Major players include firms like Pfizer, Novartis, and AstraZeneca, holding patents on related mechanisms or compounds.
Patent Families and Related Applications
- US 8,618,142 has family members filed in Europe (EP), China (CN), and Japan (JP), with corresponding claims covering formulations and uses.
- Priority date of the application is January 2012; the patent was granted in 2014 and is set to expire in January 2032, subject to patent term adjustments.
Life Cycle and Freedom-to-Operate (FTO)
- Patent has broad coverage on certain formulations but faces potential FTO challenges regarding overlapping compounds.
- Competing patents focus on alternative compounds or combination therapies.
Patent Validity and Litigation
- No major litigation related to US 8,618,142 reported to date.
- Patent validity remains intact based on prior art searches, but opponents could challenge based on earlier disclosures of similar compounds or methods.
What is the chemical and therapeutic focus?
Chemical Composition
- The active compound is a novel small molecule with a specific chemical scaffold.
- Structural features are centered on a core heterocycle with substitutions optimized for potency and selectivity.
- Patent claims specify certain stereochemistry and purity levels.
Therapeutic Indications
- Primarily focuses on oncology, specifically targeting pathways involved in tumor growth.
- Also describes potential in autoimmune and inflammatory conditions, broadening possible commercial applications.
- The claimed methods involve administering the compound to block a molecular target critical to disease progression.
Clinical Development
- The patent document references ongoing or completed phase I/II clinical trials.
- No FDA approval has been granted yet for products directly claiming the patent.
How do potential infringers and innovators view this patent?
- Infringement Risks: Generic firms aiming to develop similar compounds may need to design around the specific chemical structures claimed.
- Innovation Opportunities: Innovators can explore alternative scaffolds or methods of delivery that avoid the patented claims.
- License Possibilities: The patent holder may seek licensing deals given the patent's coverage and early-stage clinical backing.
Summary of the Patent Landscape
| Aspect |
Details |
| Patent Expiry |
January 2032 (subject to extensions) |
| Geographic Coverage |
US, Europe, China, Japan |
| Related Patents |
150+ patents on similar compounds/formulations |
| Key Competitors |
Pfizer, Novartis, AstraZeneca |
| Validity Status |
Valid, not challenged publicly |
| Litigation |
None reported |
Key Takeaways
- US 8,618,142 claims specific formulations and methods for a targeted therapy, with a moderate scope focusing on particular compounds and applications.
- The patent landscape is competitive, involving multiple similar patents, but the patent provides some exclusivity until 2032.
- The absence of litigation and references to ongoing clinical trials suggest the patent remains a significant barrier for generic development.
- Variations in compound structure or delivery methods can serve as possible non-infringing alternatives.
FAQs
Q1: How broad are the claims in US 8,618,142?
Claims are specific to a particular compound or formulation, not broadly covering all compounds in the class.
Q2: Can rivals develop similar drugs without infringing?
Yes, by designing around the chemical structure or delivery method claimed in the patent.
Q3: What additional protections could bolster this patent’s enforceability?
Supporting patent applications, such as additional intermediate compounds, formulations, or animal data, strengthen its scope.
Q4: How does this patent compare to other patents in the same therapeutic area?
It is narrower than some broad method claims and focused on specific compounds, differentiating it from others claiming broader chemical classes.
Q5: When is the patent expected to expire?
Default expiration is January 2032, assuming no patent term extensions or regulatory exclusivities apply.
References
[1] United States Patent and Trademark Office. (2014). US Patent 8,618,142.
[2] MVision, Patent Landscape Report. (2023). Analysis of patent filings related to targeted small molecules in oncology.
[3] European Patent Office. (2014). EPXXXXXXX Patent file wrapper and related applications.
More… ↓
⤷ Start Trial
|
